Table 3 Factors associated with immunovirological discordance at 12 months on antiretroviral therapy at univariate and multivariate logistic regression

Age (years)

 < 30

4 (16.00)

1

1

 30–39

15 (60.00)

1.83 (0,54–6.20)

1.55 (0.39–6.10)

 ≥ 40

6 (24.00)

1.97 (0.47–8.16)

1.76 (0.33–9.28)

Marital status (couple life)

 No

4 (16.00)

1

 Yes

21 (8400)

0.61 (0.19–2.00)

BMI Class

 < 18,5

6 (24.00)

1

 18,5–25

15 (60.00)

1.06 (0.36–3.08)

 > 25

4 (16.00)

2.44 (0.52–11.56)

WHO clinical stage

 1

3 (12.00)

1

1

 2

8 (32.00)

0.99 (0.22–4.48)

0.82 (0.13–4.98)

 3 and 4

14 (56.00)

1.08 (0.26–4.51)

1.28 (0.24–6.65)

CD4 + T cell count (cells/µl)

 < 200

11 (44.00)

1

1

 200–349

7 (28.00)

3.50 (1.13–10.83)

4.15 (1.13–15.22)

 350–500

7 (28.00)

21.00 (3.85–114.51)

17.50 (2.68–114.31)

ART NNRTIs initiated

 Nevirapine

5 (20.00)

1

 Efavirenz

20 (80.00)

1.89 (0.63–5.61)

 Protease inhibitor

–

ART NRTIs initiated

 Tenofovir

6 (24.00)

1

1

 Zidovudine

17 (68.00)

0.54 (0.16–1.75)

1.19 (0.27–5.29)

 Stavudine

2 (8.00)

0.12 (0.02–0.74)

0.28 (0.04–2.11)

ART Adherence

 < 95%

6 (24)

1

 ≥ 95%

19 (76)

2.00 (0.72–5.56)